EUTM file information
018434526
XLenti March 21, 2021
Trademark Summary
The trademark application XLenti was filed by Oxford Genetics Ltd, a corporation established under the laws of the United Kingdom of Great Britain and Northern Ireland (the "Applicant"). The application was published for oppositions on April 15, 2021, and it was registered by office on July 22, 2021 without any oppositions.
The application was filed in English (German was selected as the second language).
Goods And Services
The mark was filed in class 1 with following description of goods:Chemical and biological substances for use in science and industry Nucleic acids Nucleic recombinant acids, synthetic deoxyribonucleic acids Chemical and biological reagents for non-medical purposes Chemical and biological reagents for scientific and research purposes Human and animal cells and parts thereof for non-medical purposes Microorganisms for non-medical purposes Human and animal cells and parts thereof for scientific and research purposes Microorganisms for scientific and research purposes Viral vectors for use in science and industry Lentiviruses, lentivirus particles and lentivirus plasmids, all for scientific and research purposes. The mark was filed in class 5 with following description of goods:Chemical and biological reagents for medical and veterinary use Diagnostic and test reagents for medical and veterinary use Human and animal cells and parts thereof for medical and veterinary purposes Microorganisms for medical and veterinary purposes Viral vectors for medical and veterinary purposes Lentiviruses, lentivirus particles and lentivirus plasmids, all for medical and veterinary use. The mark was filed in class 42 with following description of goods:Design services relating to the creation and alteration of chemical and biological reagents Design services relating to the creation and alteration of nucleic recombinant acids and synthetic deoxyribonucleic acids Design services relating to the creation and alteration of recombinant viruses Design services relating to the creation and alteration of lentiviruses, lentivirus particles and lentivirus plasmids Research, development and bioengineering services relating to lentiviruses Drug discovery services Design services relating to the creation and alteration of cell lines, elementary cells and parts thereof Design services relating to the creation and alteration of viral vectors Information and advice relating to all the aforesaid services.